Christensen MB, Lund AB, Jrgensen NR, Holst JJ, Vilsbll T, Knop FK (2020) Glucose-dependent insulinotropic polypeptide (GIP) reduces bone resorption in patients with type 2 diabetes
Regular monitoring and consultation with your providers are essential to tailoring semaglutide treatment
MT-2 has also been shown to stimulate both leptin-dependent andleptin-independent pathways, making it a more effective treatment for reducing hunger than leptin alone
Prescriptions are reviewed by licensed providers
IV infusion requires: Clinical site with infusion capability Healthcare professional supervision during administration Infusion duration typically 30-60 minutes Post-infusion monitoring period Clinical Trial Dosing# Obesity/T2D (JAMA Network Open 2021)# BELIEVE Trial (Obesity Combination)# IBM (RESILIENT, Lancet Neurology 2019)# Sarcopenia (JAGS 2017)# Dose Comparison Across Indications# The higher dose used in sarcopenia (30 mg/kg) vs obesity (10 mg/kg) may reflect different therapeutic requirements for muscle anabolism in aged, sarcopenic populations
Semaglutide typically maintains stable effectiveness throughout extended use in clinical trials
